Shares of clinical-stage biopharmaceutical company Zentalis Pharmaceuticals, Inc. (ZNTL) are rising 10 percent on Tuesday's trading after the company priced its public offering of 3.1 million shares at $48.50 per share. The offering will raise about $150.4 million in proceeds. The public offering will close on July 1.

Create Account

Dark

chart

exchange

Check out our Dark Pool Levels

Shares of clinical-stage biopharmaceutical company Zentalis Pharmaceuticals, Inc. (ZNTL) are rising 10 percent on Tuesday's trading after the company priced its public offering of 3.1 million shares at $48.50 per share. The offering will raise about $150.4 million in proceeds. The public offering will close on July 1.

RTTNews | Jun 29, 2021 11:41AM EDT

11:40 Tuesday, June 29, 2021 (RTTNews.com) - Shares of clinical-stage biopharmaceutical company Zentalis Pharmaceuticals, Inc. (ZNTL) are rising 10 percent on Tuesday's trading after the company priced its public offering of 3.1 million shares at $48.50 per share. The offering will raise about $150.4 million in proceeds. The public offering will close on July 1.

Currently trading at $54.00, the stock has traded between $25.41 and $62.79 in the past 52 weeks.

Read the original article on RTTNews ( https://www.rttnews.com/3205794/zentalis-pharma-jumps-10-after-pricing-its-secondary-offering-at-48-50.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved